Clinical Trial Update: Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of brentuximab vedotin in combination with pembrolizumab for metastatic solid tumors has completed, enrolling patients with melanoma, non-small ce…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Non-small Cell Lung Cancer
• Squamous Cell Carcinoma of the Head and Neck

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Melanoma, Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED